Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2054-2060

  Johnson, D H ^a   Paul, D M ^a   Hande, K R ^a   Shyr, Y ^a   Blanke, C ^a   Murphy, B ^a   Lewis, M ^a   De Vore III, R F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029901788     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2054     Document Type: Article

References (29)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. Ca 45:8-30, 1995
2. Stewart LA, Pignon J-P, Armer MKB, et al: A meta-analysis using individual patient data from randomised clinical trials of chemotherapy in non-small cell lung cancer: (3) Survival in the supportive care setting. Proc Am Soc Clin Oncol 13:337, 1994 (abstr)
3. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 4:702-709, 1986
4. O'Connell JP, Kris MG, Gralla RJ, et al: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604-1614, 1986
5. Lilenbaum R, Green M: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391-1402, 1993
6. Rowinsky EK, Donehower RC: Taxol: Twenty years later, the story unfolds. J Natl Cancer Inst 83:1778-1781, 1991
7. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer, J Natl Cancer Inst 85:384-388, 1993
8. Chang AY, Kim K, Click J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
9. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
10. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
11. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
12. ASCO Ad Hoc Committee. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
13. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Simon R: Confidence intervals for reporting results of clinical trials. Ann Intern Med 105:429-435, 1986
16. Johnson DH, Chang AY, Ettinger DS: Taxol (paclitaxel) in the treatment of lung cancer: The Eastern Cooperative Oncology Group experience. Ann Oncol 5:S45-S50, 1994 (suppl 6)
17. Ozols RF, Kilpatrick D, O'Dwyer P, et al: Phase I and pharmacokinetic study of Taxol and carboplatin in previoulsy untreated patients with advanced epithelial ovarian cancer: A pilot study of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 12:259, 1993 (abstr)
18. Johnson DH, Hainsworth JD, DeVore RD, et al: Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt Trial. Oncology 49:57-62, 1992 (suppl 1)
19. Kearns CM, Belani CP, Erkman K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel; Pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 14:170, 1995 (abstr)
20. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): A phase II toxicity, response, and survival analysis (FCCC 93-024). J Clin Oncol 13:1860-1870, 1995
21. Vafai D, Israel V, Zaretsky S, et al: Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:352, 1995 (abstr)
22. Rowinsky EK, Sartorius SE, Bowling MK, et al: Paclitaxel on a 3-hour schedule and carboplatin in non-small cell lung cancer: Use of maximally tolerated and clinically relevant single agent doses in combination is feasible. Proc Am Soc Clin Oncol 14:354, 1995 (abstr)
23. Belli L, LeChevalier T, Gottfried M, et al: Phase I-II trial of paclilaxel (Taxol) and cisplatin in previoulsy untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:350, 1995 (abstr)
24. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1- hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609-1614, 1995
25. Jodrell DI, Egorin MJ, Canetta RM, et al: Realtionship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
26. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
27. Arbuck SG: Paclitaxel: What schedule? What dose? J Clin Oncol 12:233-236, 1994
28. Liebmann JE, Cook JA, Lipschultz C, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68:1104-1109, 1993
29. Georgiadis MS, Russell E, Johnson BE: Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Lung Cancer 11:95, 1994 (suppl 1; abstr)